Relation Therapeutics raised $35M in Seed funding led by DCVC and NVentures to advance its osteoporosis pipeline and initiate discovery campaigns in new therapeutic areas.
Relation Therapeutics raised $35M in Seed funding led by DCVC and NVentures to advance its osteoporosis pipeline and initiate discovery campaigns in new therapeutic areas.
03/15/24, 12:33 PM
Location
Money raised
$35 million
Industry
biotechnology
Round Type
seed
Investors
Deerfield Management Company, Ark Invest, Jonathan Milner, Khosla Ventures, Magnetic Ventures, N Ventures, Dcvc
Relation Therapeutics, a biotechnology company based in London, UK, raised $35M in Seed funding led by DCVC and NVentures, with participation from other investors including Khosla Ventures, Abcam founder Jonathan Milner, ARK Invest, and Deerfield Management Company. The company intends to use the funds to advance its osteoporosis pipeline towards the clinic and initiate discovery campaigns in new therapeutic areas of high unmet need.
Company Info
Location
338 euston road
london, england, united kingdom
Additional Info
Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. An important challenge for any therapeutics company using machine learning is “ground-truth data,” or information known to be true. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems. The platform then requests new experiments to improve its predictive ability, cutting through an otherwise intractable combinatorial space.